Labcorp Holdings Inc. (LH) Q3 2024 Earnings Call Transcript Summary
Labcorp Holdings Inc. (LH) Q3 2024 Earnings Call Transcript Summary
Enterprise margins decreased by 40 basis points due to impacts.The following is a summary of the Labcorp Holdings Inc. (LH) Q3 2024 Earnings Call Transcript:
以下是Labcorp Holdings Inc. (LH) 2024年第三季度業績會交流內容摘要：
Financial Performance:
金融業績：
Labcorp reported Q3 revenue of $3.3 billion, an increase of 7% YoY.
Adjusted EPS was $3.50, up 4% YoY.
Enterprise margins decreased by 40 basis points due to impacts.
Operating income was $254 million, or 7.7% of revenue, with adjusted operating income at $441 million, or 13.4%.
Free cash flow from continuing operations for the quarter was $162 million.
Labcorp報告第三季度營業收入爲33億美元，同比增長7%。
調整後的每股收益爲3.50美元，同比增長4%。
企業利潤率由於影響下降了40個點子。
營業收入爲25400萬美元，佔營業收入的7.7%，調整後的營業收入爲44100萬美元，佔13.4%。
本季度持續經營的自由現金流爲16200萬美元。
Business Progress:
業務進展：
Labcorp expanded its diagnostic capabilities by acquiring select operating assets of Ballad Health outreach lab services and other acquisitions including select assets of Lab Works and BioReference's Health laboratory testing business.
Continued advancements in science and technology with the acquisition of Invitae and expanded collaboration with Ultima Genomics.
Launched consumer-initiated tests on Labcorp OnDemand, and planning to distribute the first over-the-counter Syphilis blood test.
Introduced a new order tracking for diagnostic customers enhancing the customer experience.
Expanded women's health solutions through Ovia Health.
Labcorp通過收購Ballad Health outreach實驗室服務的部分運營資產以及Lab Works和BioReference's Health實驗室測試業務的其他收購來擴大其診斷能力。
通過收購Invitae並拓展與Ultima Genomics的合作，Labcorp在科技領域不斷取得進展。
在Labcorp OnDemand上推出消費者發起的測試，並計劃首次分發非處方梅毒血液測試。
推出了面向診斷客戶的新訂單跟蹤功能，增強了客戶體驗。
通過Ovia Health擴展了婦女健康解決方案。
Opportunities:
機會：
The acquisition of Invitae aligns strategically with Labcorp's focus on specialty medicine and oncology, enhancing genetic testing solutions and technology.
Expansion of Labcorp OnDemand offerings adds to consumer health management capabilities.
收購Invitae與Labcorp專注於特色藥品和腫瘤學的戰略重點相一致，增強了遺傳測試解決方案和科技。
Labcorp OnDemand業務的拓展增強了消費者健康管理能力。
Risks:
風險：
Adjusted operating margin declined due to impacts from Invitae and other operational challenges.
The dependence on acquisitions for segment growth introduces risks associated with integration and market competition.
由於invitae和其他運營挑戰的影響，調整後的營業利潤率下降了。
對於業務增長依賴收購，會帶來整合和市場競爭相關的風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
